Transgenic News and Research

RSS

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

USPTO issues notice of allowance to Mirna's mir34a patent application

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a.

7 Apr 2011

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Celldex Therapeutics, Inc. today announced that new data on its preclinical therapeutic antibody program, CDX-1127, is being presented in a poster presentation at the 2011 American Association for Cancer Research 102nd Annual Meeting in Orlando, FL.

6 Apr 2011

Zebrafish research suggests new drug targets and markers to help treat melanoma

Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

Insight into traumatic brain injury

Researchers from UT Southwestern Medical Center have described for the first time how the brain's memory center repairs itself following severe trauma - a process that may explain why it is harder to bounce back after multiple head injuries.

1 Apr 2011

How brain's memory center repairs itself after severe trauma

1 Apr 2011

Zileuton can help reduce amyloid plaque formation and Alzheimer's development

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

28 Mar 2011

Molecular Therapy journal publishes Mirna's new tumor suppressor miRNA mimics data

Mirna Therapeutics, Inc. announced today the publication of new results in the journal Molecular Therapy demonstrating how a neutral lipid emulsion facilitates the systemic delivery of tumor suppressor miRNA mimics and reduces the tumor burden in the lungs of mice.

24 Mar 2011

Zebrafish model of human melanoma reveals new cancer gene

Looking at the dark stripes on the tiny zebrafish you might not expect that they hold a potentially important clue for discovering a treatment for the deadly skin disease melanoma. Yet melanocytes, the same cells that are are responsible for the pigmentation of zebrafish stripes and for human skin color, are also where melanoma originates.

24 Mar 2011

Researcher to look for genes that can suppress epileptic seizures in fruit flies

"Exceptional, Unconventional Research Enabling Knowledge Acceleration" - is the name of a rare and competitive grant that Reenan recently won from the National Institutes of Health. Beginning April 1, Reenan will use the four-year, $1.3-million award to look for genes that can suppress seizures in fruit flies that he has cleverly engineered to mimic human epilepsy.

22 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

Human growth, height, size: Reasons to be small

Almost everybody these days thinks that it is best to be tall, meaning much taller than the average traditional height of Asian populations, and even taller than the current average height of populations in high-income countries. It is also often believed – though people might be shy to admit this – that tall people are intrinsically superior to short people. The expressions 'look up to' and 'look down on' are significant.

15 Mar 2011

Novel gene therapy can promote removal of amyloid plaques and prevent Alzheimer's disease

Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.

5 Mar 2011

New study finds liver instead of the brain as source of Alzheimer’s plaques

Unexpected results from a Scripps Research Institute and ModGene, LLC study could completely alter scientists' ideas about Alzheimer's disease—pointing to the liver instead of the brain as the source of the "amyloid" that deposits as brain plaques associated with this devastating condition. The findings could offer a relatively simple approach for Alzheimer's prevention and treatment.

4 Mar 2011

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.

1 Mar 2011

NIH-funded study finds way to reduce transmission of malaria to humans

Spraying malaria-transmitting mosquitoes with a genetically modified fungus can kill the malaria parasite without harming the mosquito, potentially reducing malaria transmission to humans, according to a new study published in the journal Science. Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the study was led by Raymond J. St. Leger, Ph.D., of the University of Maryland, College Park.

25 Feb 2011

Transgenic fungal approach can fight against malaria and bug-borne diseases

New findings by a University of Maryland-led team of scientists indicate that a genetically engineered fungus carrying genes for a human anti-malarial antibody or a scorpion anti-malarial toxin could be a highly effective, specific and environmentally friendly tool for combating malaria, at a time when the effectiveness of current pesticides against malaria mosquitoes is declining.

24 Feb 2011

Deactivation of tau gene may help reverse memory loss in Alzheimer disease

Amyloid-beta and tau protein deposits in the brain are characteristic features of Alzheimer disease. The effect on the hippocampus, the area of the brain that plays a central role in learning and memory, is particularly severe. However, it appears that the toxic effect of tau protein is largely eliminated when the corresponding tau gene is switched off.

16 Feb 2011